Is There a Cure for Diabetes? Remission vs. Reality

No medical authority recognizes a cure for either type 1 or type 2 diabetes, but type 2 diabetes can enter what clinicians formally call “remission,” a state where blood sugar stays in the normal range without medication. The distinction between remission and cure is not just semantic. Remission means the disease process can return, and it often does. Understanding why remission happens, how long it lasts, and who it works for reveals a more complicated picture than the hopeful headlines suggest.

What Remission Actually Means

A 2021 international consensus group settled on a specific definition: remission of type 2 diabetes means an HbA1c below 6.5% measured at least three months after stopping all glucose-lowering medications.¹ The group deliberately chose the word “remission” over “reversal” or “cure” because it carries a built-in acknowledgment that the condition can come back. This framing borrowed from oncology, where remission has long been understood as a period without active disease, not a guarantee that the disease is gone forever.

That distinction matters because people in remission still carry the underlying susceptibility that gave them diabetes in the first place. Their beta cells, the insulin-producing cells in the pancreas, may have recovered function but often remain more vulnerable than those of someone who never developed diabetes. And the metabolic changes that led to the disease, including fat accumulation in the liver and pancreas, can return if weight is regained or lifestyle changes slip.

How Weight Loss Drives Remission

The most convincing evidence for type 2 diabetes remission comes from aggressive weight-loss interventions. Research testing what is known as the Twin Cycle Hypothesis has shown that type 2 diabetes is a potentially reversible metabolic state, and that roughly 10 to 15% weight loss can normalize liver fat content, reduce fat export to the pancreas, and allow beta cells to recover their ability to respond to glucose.² In people who responded to weight loss, the pancreas’s ability to release insulin in a rapid first burst improved and stayed improved during weight maintenance. In non-responders, that recovery simply did not happen.³

This is a critical finding: whether remission succeeds depends heavily on how much insulin-producing capacity remains. People diagnosed recently, whose beta cells have not been damaged for years, are far more likely to recover function. The longer someone has had diabetes, the more beta cells have been lost, and the harder it becomes to coax the remaining ones back into working order.

The Dietary Approaches That Work

The Diabetes Remission Clinical Trial, known as DiRECT, became the landmark study in this space. It used a structured program of total diet replacement with a low-calorie formula diet of about 825 to 853 calories per day for 12 to 20 weeks, followed by gradual food reintroduction and ongoing weight-management support.⁴ Participants also stopped their diabetes and blood-pressure medications at the start. In the intervention group, about 62% achieved remission at one year. But that proportion dropped steadily, falling to roughly 13% by year five.⁵

That five-year decline is not a failure of the concept so much as a reflection of how hard sustained weight loss is. Most participants regained some weight over time, and with it, their blood sugar crept back up. The subset who maintained their weight loss tended to stay in remission. The message is straightforward if uncomfortable: remission is achievable, but keeping it requires permanent change.

Low-carbohydrate diets represent another pathway. A meta-analysis found that low-carb diets meaningfully increased the proportion of people who brought their HbA1c below 6.5%, but when the stricter criterion was applied, requiring both normal HbA1c and no diabetes medications, the benefit was much smaller.⁶ In a general practice setting where patients were given low-carbohydrate dietary advice, about 77% of those in their first year after diagnosis achieved an HbA1c below 6.5% without any diabetes medication.⁷ That high rate likely reflects how recently those patients had been diagnosed. A recent randomized trial also found that the composition of a low-calorie diet matters: a formula diet higher in fiber and protein and lower in carbohydrate and fat produced remission in 91% of participants, compared with 56% on a standard formula.⁸

Bariatric Surgery and Long-Term Outcomes

Bariatric surgery produces the highest remission rates of any intervention, partly because the weight loss is larger and partly because the surgical rearrangement of the gut changes hormonal signaling in ways that go beyond what weight loss alone explains. Evidence consistently shows that surgery outperforms the best medical management for diabetes resolution in people with obesity, and that procedures like gastric bypass achieve higher remission rates than less invasive options like gastric banding.⁹

But surgery is not a permanent fix for everyone either. A ten-year follow-up study found that about 31% of patients maintained complete remission a decade after surgery, with another 15% in partial remission. Roughly a quarter of those who initially achieved remission experienced a return of their diabetes.¹⁰ Another long-term study found similar patterns: about 24% achieved lasting complete remission, another 26% partial remission, and 19% of initial remitters had their diabetes come back.¹¹

The predictors of lasting remission are consistent across studies: people who had diabetes for a shorter time before surgery, who had lower HbA1c levels going in, who were on fewer medications, and who lost more excess weight in the first year all fared better. In a five-year study of relapse, longer diabetes duration and higher preoperative HbA1c independently predicted a return of the disease, while greater first-year weight loss protected against it.¹² Most relapses in that study clustered between years four and five, suggesting that the honeymoon period after surgery does not last indefinitely.

Why Remission Still Pays Off Even When It Doesn’t Last

Even temporary remission appears to yield lasting health benefits. A population-based study found that people who achieved remission at any point during a seven-year follow-up had significantly lower risks of cardiovascular events and both large-vessel and small-vessel complications compared with those who never achieved remission.¹³ A pooled analysis of cohort studies comparing surgery to nonsurgical management found that surgical patients had dramatically lower rates of small-vessel complications, large-vessel events, and death over at least five years of follow-up.¹⁴

Part of the explanation for this lasting benefit involves what researchers call a “legacy effect.” High blood sugar causes changes at the cellular level, including modifications to how genes are expressed and an overproduction of damaging molecules called superoxide anions. These harmful processes can continue even after blood sugar returns to normal.¹⁵ The flip side of the legacy effect is that getting blood sugar under control early, before years of damage accumulate, may prevent some of these lasting changes from taking hold. Every year spent in remission is a year the body is not absorbing the damage of uncontrolled glucose.

Type 1 Diabetes Is a Different Problem Entirely

Everything discussed so far applies to type 2 diabetes. Type 1 is a fundamentally different disease in which the immune system destroys the insulin-producing beta cells. There is no remission through weight loss or diet because the core problem is autoimmune destruction, not metabolic overload. Despite major advances in insulin delivery and blood glucose monitoring, there is no cure, and pancreas or islet transplantation, while attractive in theory, remains vulnerable to both recurring autoimmunity and transplant rejection.¹⁶

The most significant recent advance for type 1 is teplizumab, an antibody that targets immune cells involved in beta-cell destruction. In a trial of high-risk relatives of people with type 1 diabetes, a single course of teplizumab delayed the diagnosis by a median of about two years compared to placebo. Over longer follow-up, half of those treated with teplizumab remained diabetes-free compared to about 22% on placebo.¹⁷ The drug does not prevent type 1 diabetes outright; it delays it. But for a disease where every month of preserved beta-cell function matters, a delay of two or more years from a single treatment course is meaningful.¹⁸

Islet Transplantation and Stem Cells

For people who already have type 1 diabetes, islet transplantation offers a more direct approach: take insulin-producing cells from a donor pancreas and infuse them into the recipient’s liver, where they can graft and begin producing insulin. A 20-year Italian study found that about 44% of 79 recipients achieved insulin independence for a median of six years. Graft survival, meaning the transplanted cells were still producing detectable insulin, was 86% at one year, 65% at five years, and about 40% at 20 years. Those who received a larger islet mass with an optimized drug regimen did better, with 73% achieving insulin independence and grafts lasting a median of nearly ten years.¹⁹ A North American consortium study confirmed that islet transplantation provides durable improvement in blood sugar control and nearly eliminates dangerous episodes of severe low blood sugar, with more than 90% of recipients remaining free of severe hypoglycemia during long-term follow-up.²⁰

The catch is immunosuppression. Recipients must take drugs that dampen the immune system to prevent rejection, and those drugs carry their own risks, including infections and sensitization to future transplants. In the Italian study, 44% of patients had adverse events related to their immunosuppressive therapy.¹⁹ Islet transplantation is typically reserved for people with dangerous hypoglycemia unawareness, where the risk of severe low blood sugar outweighs the risks of immunosuppression.

Stem cell research represents the frontier that could someday bypass the donor shortage altogether. The idea is to grow insulin-producing cells from a patient’s own reprogrammed cells, potentially eliminating the need for both donor organs and immunosuppression.²¹ Early case reports have been encouraging, but these remain very early-stage. Scaling the technology, ensuring safety, and proving long-term efficacy will take years of additional research.

The Role of Newer Medications

The explosion of GLP-1 receptor agonists and related drugs has added a new wrinkle to the remission conversation. Tirzepatide, which targets two gut hormone receptors simultaneously, produces substantial weight loss and dramatic drops in HbA1c. Case reports have documented diabetes remission after temporary tirzepatide treatment, with blood sugar remaining normal after the drug was stopped.²² Whether this represents a scalable pathway to remission or works only in a narrow subset of patients, likely those with recent-onset diabetes and significant remaining beta-cell function, remains to be determined by larger trials.

The conceptual tension here is that the consensus definition of remission requires being off all glucose-lowering medications. If someone needs to stay on a GLP-1 drug to maintain normal blood sugar, they are being well-treated, not in remission. This is not a technicality. It reflects the core difference between controlling a disease and resolving it. Still, the line is blurring. If a short course of medication can restore metabolic function that persists after the drug is stopped, that looks a lot like what dietary interventions achieve, just with pharmacological help to get there.

The Psychological Side of Remission

Remission carries an emotional weight that is easy to underestimate. Qualitative research with people who achieved remission through bariatric surgery found that many experienced deep stigma around both their obesity and their diabetes, leading to shame and an inability to seek help. Patients tended to view remission as a personal responsibility and regarded any return of medications as a sign of personal failure.²³ This framing is harmful. Diabetes relapse after surgery or diet is driven primarily by biology, including the progressive decline of remaining beta cells and the body’s powerful drive to regain lost weight. Treating it as a character failure ignores the physiology.

The fear of complications also does not disappear with remission. Research on people managing diabetes-related complications described chronic anxiety and persistent fear of recurrence, along with emotional exhaustion that led to burnout around self-care.²⁴ People in remission often report a similar vigilance: monitoring their weight, checking their blood sugar periodically, worrying that the other shoe will drop. The psychological experience of remission is not the same as being free of the disease.

Who Benefits Most and the Economics of Remission Programs

The consistent predictors across all approaches, whether diet, surgery, or medication, are shorter diabetes duration, better starting blood sugar control, and greater weight loss. If you have had type 2 diabetes for less than six years, still have meaningful insulin production, and can achieve and maintain significant weight loss, your chances of remission are substantially better than someone who has had the disease for 15 years and is on multiple medications. This is not a judgment of effort; it reflects how much beta-cell capacity remains to be rescued.

Health systems have started paying attention to the economics. The DiRECT program cost about £1,691 per participant over five years but saved roughly £2,091 in healthcare costs over the same period, primarily from reduced hospital admissions.²⁵ Over a full lifetime horizon, the intervention was modeled to produce meaningful gains in quality of life while saving the health system money, becoming cost-saving within about six years.²⁶ Scotland has been evaluating the rollout of a digital remission program based on this evidence.²⁷ These are not marginal savings. For a disease that costs health systems billions annually, even modest remission rates at scale translate into enormous numbers.

The Gut Microbiome Connection

An emerging area of research looks at how changes in gut bacteria might contribute to diabetes remission. Animal studies have shown that certain dietary interventions promote the growth of bacterial species linked to beneficial short-chain fatty acids like butyrate and propionate, which are inversely associated with type 2 diabetes.²⁸ The thinking is that the metabolic improvements seen with dietary change are not driven purely by calorie restriction and weight loss. The composition of the gut microbiome may play an independent role, reshaping how the body processes glucose and responds to insulin. This research is still early, mostly in animal models, but it could eventually help explain why some dietary compositions work better than others for remission and why individual responses vary so dramatically.